Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Biomarkers predicting tumor response and evasion to anti-angiogenic therapy.

Jahangiri A, Aghi MK.

Biochim Biophys Acta. 2012 Jan;1825(1):86-100. doi: 10.1016/j.bbcan.2011.10.004. Epub 2011 Oct 30. Review.

PMID:
22067555
2.

Biomarkers of response and resistance to antiangiogenic therapy.

Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG.

Nat Rev Clin Oncol. 2009 Jun;6(6):327-38. doi: 10.1038/nrclinonc.2009.63. Review.

3.

Biomarkers in tumor angiogenesis and anti-angiogenic therapy.

Pircher A, Hilbe W, Heidegger I, Drevs J, Tichelli A, Medinger M.

Int J Mol Sci. 2011;12(10):7077-99. doi: 10.3390/ijms12107077. Epub 2011 Oct 21. Review.

4.

Cellular and soluble markers of tumor angiogenesis: from patient selection to the identification of the most appropriate postresistance therapy.

Bertolini F, Marighetti P, Shaked Y.

Biochim Biophys Acta. 2010 Dec;1806(2):131-7. doi: 10.1016/j.bbcan.2010.05.004. Epub 2010 May 31. Review.

PMID:
20685298
5.

Anti-angiogenesis therapy in cancer: current challenges and future perspectives.

Shojaei F.

Cancer Lett. 2012 Jul 28;320(2):130-7. doi: 10.1016/j.canlet.2012.03.008. Epub 2012 Mar 13. Review.

PMID:
22425960
6.

Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.

Abdollahi A, Folkman J.

Drug Resist Updat. 2010 Feb-Apr;13(1-2):16-28. doi: 10.1016/j.drup.2009.12.001. Epub 2010 Jan 12. Review.

PMID:
20061178
7.

Tumor endothelial markers as a target in cancer.

Ribatti D, Ranieri G, Basile A, Azzariti A, Paradiso A, Vacca A.

Expert Opin Ther Targets. 2012 Dec;16(12):1215-25. doi: 10.1517/14728222.2012.725047. Epub 2012 Sep 17. Review.

PMID:
22978444
8.

Predicting benefit from anti-angiogenic agents in malignancy.

Jubb AM, Oates AJ, Holden S, Koeppen H.

Nat Rev Cancer. 2006 Aug;6(8):626-35. Epub 2006 Jul 13. Review.

PMID:
16837971
9.

Anti-angiogenic therapies in cancer: achievements and open questions.

Ruegg C, Mutter N.

Bull Cancer. 2007 Sep;94(9):753-62. Review.

10.

[Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].

Jary M, Borg C, Bouché O, Kim S, André T, Bennouna J.

Bull Cancer. 2015 Sep;102(9):758-71. doi: 10.1016/j.bulcan.2015.05.002. Epub 2015 Jul 29. Review. French.

PMID:
26232849
11.

Clinical biomarkers of angiogenesis inhibition.

Brown AP, Citrin DE, Camphausen KA.

Cancer Metastasis Rev. 2008 Sep;27(3):415-34. doi: 10.1007/s10555-008-9143-x. Review.

12.

Biomarkers in the development of anti-angiogenic therapies for ovarian cancer.

Raja FA, Hook JM, Ledermann JA.

Cancer Treat Rev. 2012 Oct;38(6):662-72. doi: 10.1016/j.ctrv.2011.11.009. Epub 2011 Dec 29. Review.

PMID:
22209539
13.

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN.

Curr Pharm Des. 2007;13(35):3545-58. Review.

PMID:
18220791
14.

Antiangiogenic therapies: going beyond their limits.

Moserle L, Jiménez-Valerio G, Casanovas O.

Cancer Discov. 2014 Jan;4(1):31-41. doi: 10.1158/2159-8290.CD-13-0199. Epub 2013 Dec 19. Review.

16.

Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?

Sessa C, Guibal A, Del Conte G, Rüegg C.

Nat Clin Pract Oncol. 2008 Jul;5(7):378-91. doi: 10.1038/ncponc1150. Epub 2008 Jun 17. Review.

PMID:
18560389
17.

Endostatin: the logic of antiangiogenic therapy.

Abdollahi A, Hlatky L, Huber PE.

Drug Resist Updat. 2005 Feb-Apr;8(1-2):59-74. Epub 2005 Apr 7. Review.

PMID:
15939343
18.

Resistance to antiangiogenic therapies.

Bartolotti M, Franceschi E, Poggi R, Tosoni A, Di Battista M, Brandes AA.

Future Oncol. 2014 Jun;10(8):1417-25. doi: 10.2217/fon.14.57. Review.

PMID:
25052752
19.

Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies.

Crawford Y, Ferrara N.

Trends Pharmacol Sci. 2009 Dec;30(12):624-30. doi: 10.1016/j.tips.2009.09.004. Review.

PMID:
19836845
20.

Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.

Shojaei F, Ferrara N.

Drug Resist Updat. 2008 Dec;11(6):219-30. doi: 10.1016/j.drup.2008.09.001. Epub 2008 Oct 23. Review.

PMID:
18948057

Supplemental Content

Support Center